News about Contineum Therapeutics Inc

Breakthrough in Biopharmaceutical Science Promising Data on PIPE-307, an M1 Receptor Antagonist for Relapse-Remitting...
Aug 01 2024
AbstractThe development of novel therapeutic agents has become an imperative focus in the biomedical field, particularly for conditions lacking fully...

Sarah Boyce Joins Contineum Therapeutics Board A Step Towards Augmenting Biopharmaceutical Therapies
Jun 25 2024
Sarah Boyce Appointed to Contineum Therapeutics* Board of Directors: Strengthening the Clinical Stage Biopharmaceutical Company*s Drug Development Str...

Contineum Therapeutics Strengthens Leadership Team with the Strategic Appointment of Sarah Boyce to its Board of Dire...
Jun 24 2024
*Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors*SAN DIEGO ?? Contineum Therapeutics, Inc. (Nasdaq: CTNM), a forward...